GEN News Highlights

In the drugmaker’s largest-ever collaboration with a Swedish academic institution, AstraZeneca is teaming up with Karolinska Institutet to establish a cardiovascular and metabolic disease research center.

The phama giant will contribute up to $100 million over five years to the Karolinska Institutet/AstraZeneca Integrated Cardio Metabolic Centre, in which scientists from both organizations will work under the same director, for which recruitment is underway. All told, the center will house up to six research groups involving 20 to 30 scientists from both organizations, who will become full-time employees at the center.

AstraZeneca and Karolinska said the center’s aim is to identify and validate novel targets within cardiometabolic diseases, with particular focus on cardiac regeneration and diabetic nephropathy via small molecules and biologics.

In a statement, Stockholm-Uppsala Life Science said the establishment of this center is one of several “clear indicators that the sector is in robust health despite the recent closing of AstraZeneca’s neuroscience facility” in the region.

“We believe that this new collaboration model, with research groups located under one roof and working in a fully integrated manner will be prove a success for both industry and academia,” Karolinska president Anders Hamsten said in a statement.

Added Marcus Schindler, vp, head of CVMD iMed, AstraZeneca: “We have worked side by side with academic institutions in the past, but this is the first time that AstraZeneca will fully integrate our research teams with an academic institution. We believe that this will speed up the progression from groundbreaking research into the delivery of new medicines and advance our scientific leadership in cardiovascular and metabolic research.”

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.